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Glucocorticoids (GCs) belong to the family of steroid hormones and 
are synthesized in the fascicular zone of the adrenal cortex, whose 
primary function is to maintain body homeostasis. The antiinflam‐
matory properties of GCs came to prominence when cortisol was 
used in the suppression of the clinical manifestations of rheumatoid 
arthritis 60 years ago, and they have been used in medicine since 
then.1 For this contribution, in 1950 the Nobel Prize in Physiology 
or Medicine was awarded to Kendall and Reichstein. The clinical 
demand for GCs rapidly increased and numerous compounds were 
synthesized. Among them, prednisone, prednisolone, dexametha‐
sone, and triamcinolone first appeared in the 1950s and are still in 
use.2
GCs exert their antiinflammatory effects by binding to the glu‐
cocorticoid receptor (GR) and by modulating gene expression. In the 
absence of its ligand, the GR is predominantly located in the cyto‐
plasm, in a complex containing multiple proteins such as the chaper‐
ones Hsp90, Hsp50 and Hsp70, and the immunophilins FKBP51 and 
FKBP52. Upon ligand binding, the GR undergoes a conformational 
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Abstract
Antihistamines and glucocorticoids (GCs) are often used together in the clinic, in sev‐
eral inflammatory‐related situations. Even though there is no clear rationale for this 
drug association, the clinical practice is based on the assumption that due to their 
concomitant antiinflammatory effects, there should be an intrinsic benefit in their 
coadministration. Our group has studied the molecular interaction between the his‐
tamine H1 receptor and the glucocorticoid receptor (GR) signaling pathways, showing 
an enhancing effect on GC‐induced GR transcriptional activity induced by antihista‐
mines. We hypothesize that the existence of this synergistic effect could contribute 
in reducing the GCs clinical doses, ineffective by itself but effective in combination 
with an antihistamine. This could result in a therapeutic advantage as the GC‐desired 
effects may be reinforced by the addition of an antihistamine and, as a consequence 
of the dose reduction, GC‐related adverse effects could be reduced or at least miti‐
gated. Here we discuss the potential therapeutic applications of this cotreatment 
seeking to evaluate its usefulness, especially in inflammatory‐related conditions.
K E Y W O R D S
antihistamines, drug association, glucocorticoid receptor, glucocorticoids, histamine H1 
receptor, inflammation
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change resulting in dissociation from this multiproteic complex and 
nuclear translocation.3 Once in the nucleus, GR can positively regu‐
late (or transactivate) anti‐inflammatory genes expression, mainly by 
binding directly to promoter regions of target genes, or negatively 
regulating, or transrepressing, the expression of proinflammatory 
genes, mostly by physical interaction with other transcription fac‐
tors such as nuclear factor κB (NF‐κB) or activator protein 1 (AP‐1). 
A growing body of evidence has shown some rapid effects on inflam‐
mation, which would not be mediated by changes in gene expres‐
sion. However, much remains to be clarified in relation with the role 
of these mechanisms in their antiinflammatory action.4
Nowadays, GCs are among the most widely prescribed drugs in 
clinical practice because of their strong antiinflammatory and im‐
munosuppressive effects. They represent a standard therapy for 
several autoimmune, inflammatory, and allergic disorders, such as 
rheumatoid arthritis, asthma, lupus erythematosus, inflammatory 
bowel disease and transplant rejection.5 Nevertheless, therapy is 
commonly associated with a large amount of serious adverse effects 
including osteoporosis, dyslipidemia, body fat redistribution, muscle 
wasting and atrophy, insulin resistance, glucose intolerance and even 
diabetes.6 The occurrence and severity of the GC are determined 
by the duration, dosage and dosing regime, the nature and its route 
of administration as well as by the individual susceptibility of each 
patient.7 The main challenge always was, and still remains, to im‐
prove their antiinflammatory actions while minimizing their adverse 
metabolic effects.8
2  | TR ANSAC TIVATION VS 
TR ANSREPRESSION
As mentioned, to maintain homeostasis, GCs act on almost every 
cell of the human body, regulating physiological processes includ‐
ing intermediary metabolism, immune function, skeletal growth, 
cardiovascular function, reproduction, and cognition. According to 
this, it becomes nearly impossible to separate the antiinflamma‐
tory effects from the metabolic undesired effects. The hypothesis 
whereby the antiinflammatory effects of GCs are mainly determined 
by the transpression (TR) of GR of pro‐inflammatory transcription 
factors, while their adverse effects are induced by transactivation 
(TA) of genes, has led to the identification of dissociated GCs or se‐
lective	GR	 agonists	 (SEGRAs).	 RU24782,	 RU24858,	 and	RU40066	
have been shown to reduce TA activity but still retain strong anti‐
inflammatory activity. Unfortunately, to date, only two compounds 
have been evaluated in clinical trials, Mapracorat for topical applica‐
tions and Fosdagrocorat for rheumatoid arthritis treatment.9,10 Their 
lack of efficacy is probably due to the importance of TA in resolving 
inflammation. The continuous identification of new TA‐dependent 
genes with antiinflammatory properties supports this notion and 
reflects the importance of TA in these processes. In addition, the 
development of those initially promising compounds was slowed 
down due to the occurrence of clinical bone‐related adverse ef‐
fects.	Several	studies	have	proved	that	GCs’	adverse	effects	such	as	
osteoporosis or muscular atrophy, also occur through TR.0.11 In this 
context, since TA and TR involve both antiinflammatory and GR‐re‐
lated side effects, dissociating them by dissociating TA and TR has 
become a chimera.
3  | GR MODUL ATORS
Because of the complexity of the GR biology it has been hypoth‐
esized that different GR conformations would lead to different 
transcriptional profiles and ultimately to different pharmacologi‐
cal outcomes.12,13 This has driven the search towards ligands that 
activate the GR in specific conformations to selectively modulate 
its	function	(SEGRMs),	broadening	from	steroidal	to	nonsteroidal	
scaffolds. One example is the nonsteroidal Compound A, which 
was classified as a selective GR modulator because it was able to 
partially interfere selectively with GC‐activated TA‐related gene 
expression eliciting a different conformation of GR in relation to 
classic GCs.14 Derived from this, the two most extreme modula‐
tors	would	be	those	that	induce	only	GR	monomer	(SEMOGRAMs)	
or	 dimer	 (SEDIGRAMs)	 conformations.	 Since	 the	 treatment	 of	
different diseases will mainly benefit from monomeric or dimeric 
GR	 actions,	 it	 has	 been	 hypothesized	 that	 SEMOGRAMs	 may	
be	 useful	 in	 chronic	 inflammatory	 diseases,	 while	 SEDIGRAMs	
may be useful in acute inflammatory conditions. However, 
the assumption that different GCs may lead to different GR 
dimerization degrees and to different transcriptional activi‐
ties requires further validation and consequently, there is a 
need for more clinical evidence to evaluate the GR dimerization 
hypothesis.15
4  | COMPLEMENTARY THER APIES
Another approach to deal with GC‐related adverse effects is the 
addition of a different drug to a corticoid‐based therapy, aiming to 
reduce the dose of corticoid and consequently its side effects. As 
mentioned before, the occurrence and severity of the secondary ef‐
fects are mainly determined by the duration and dosage of the treat‐
ment.7 Asthma is a well‐known example where different add‐on 
therapies are recommended. GCs are commonly used together with 
β2‐adrenoceptor (β2R) agonists, theophylline or anti‐leukotrienes, 
being the first one, the most effective combination.16 Due to its 
bronchodilator effect, it was suggested that the addition of β2R ago‐
nists may have complementary actions to GCs on the physiopathol‐
ogy of asthma. At the molecular level, it has been described synergic, 
or at least additives effects, since it was reported that β2R agonists 
increase GC‐induced GR nuclear localization and its transcriptional 
activity.17 More recent and promising, but still preclinical, strate‐
gies	to	circumvent	GCs’	side	effects	 involve	the	stimulation	of	the	
crosstalk between the GR and the peroxisome proliferator‐activated 
receptor (PPARs), as their signaling pathways have overlapping and 
complementary roles in many tissues. By combining GR with PPARα 
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stimulation, their antiinflammatory effects might be additive, but not 
their side effects.15
5  | ANTIHISTAMINES
The first antihistamines have arisen through the finding of the an‐
tihistaminic effects associated with piperoxane by Daniel Bovet 
and	 Anne‐Marie	 Staub	 in	 1937.	 For	 his	 work	 on	 antihistamines	
and curare, Bovet was awarded the Nobel Prize in Physiology 
or Medicine in 1957. However, it was more than 20 years earlier 
when	Sir	Henry	Dale	demonstrated	the	effects	of	histamine	(HA)	
on the stomach's smooth muscle and the respiratory tract, as well 
as its vasopressor and shock‐related effects when injected into 
animals.18 The years following saw the emergence of several re‐
ports leading to the establishment of the role of HA in allergic 
and anaphylactic processes. These findings triggered the search 
for antagonists that were able to prevent the pathological effects 
of HA at the Pasteur Institute, where Bovet worked. Based on the 
common characteristics between HA, acetylcholine and adrena‐
line, in 1937 related compounds started to be explored leading to 
the discovery of piperoxane and its associated compounds, capa‐
ble of preventing the lethal effects induced by HA administration 
in guinea pigs.19
In 1942 the first antihistamine was approved for its use in hu‐
mans, and nowadays antihistamines represent the largest group of 
medicines used in allergic disorders, with more than 45 clinical anti‐
histamines available worldwide. Initially classified as antagonists of 
the histamine H1 receptor (H1R), they have been reclassified as in‐
verse agonists, capable of stabilizing the inactive form of the H1R.
20‐
22 Through this mechanism of action and also by antagonizing the 
effects of HA at the H1R, these drugs interfere with the allergic‐in‐
flammatory processes, becoming the second‐generation antihista‐
mines, medications of choice in patients with allergic rhinitis (AR), 
conjunctivitis allergic and urticaria. Antihistamines are also used in 
disorders where there is no strong clinical evidence regarding their 
efficacy, such as atopic dermatitis (AD), anaphylaxis, nonallergic 
angioedema, otitis media, sinusitis, insomnia, anxiety, migraine and 
other vestibular disorders.23 Even when they are indicated for pa‐
tients with allergic rhinitis with concomitant asthma, they are not 
used in patients with asthma.24
6  | ANTIHISTAMINES AND 
GLUCOCORTICOIDS
Antihistamines, as well as glucocorticoids, are widely used for the 
treatment of allergic and inflammatory conditions. It is important 
to highlight that the targets with the greatest number of approved 
drugs are their receptors, the GR and the H1R.
25 Even when there is 
no clear rationale for this drug association, they are commonly used 
together in a number of inflammatory‐related clinical situations. This 
clinical practice has been stablished based on the assumption that 
there should be an intrinsic benefit in their coadministration due to 
their antiinflammatory effects.26
It has been shown that the combination of antihistamines and 
corticoids is the most widely used choice to treat all types of AR.27 
Several	 clinical	 trials	 have	 shown	 the	 benefits	 of	 the	 combination	
of the antihistamine azelastine (AZE) and the corticoid fluticasone 
(FLU), resulting in the patent granting of the first steroid plus anti‐
histamine nasal spray (Dymista®) along with two other steroid com‐
binations.28 Recently published guidelines also position AZE + FLU 
as a first‐line treatment for moderate to severe AR, in preference 
to an inhaled GC.29 The 2016 update to the Allergic Rhinitis and 
its Impact on Asthma (ARIA) guidelines recommends this combina‐
tion for seasonal AR.30 To date, AZE + FLU is the only combination 
available for the treatment of AR. Its efficacy is ascribed to the an‐
tiallergic and antiinflammatory effects of the antihistamine in the 
early phase reactions and the potent inhibition of the late‐phase 
allergic reactions by the corticoid, resulting in significant additive 
effects.31 Nevertheless, nothing is known about the molecular inter‐
action between the intracellular signaling pathways of both ligands. 
Pathophysiological gaps related to this combined therapy claim for 
further study of the molecular mechanisms of action.32
Likewise, AD therapy is another example of the concomitant 
use of antihistamines and corticoids. This inflammatory and chronic 
skin disease is widely treated with topic corticoids, even though the 
treatment presents many adverse effects and its efficacy and mech‐
anism of action are not well understood. Antihistamines have been 
used jointly with corticoids for AD treatment albeit little is known 
about its usefulness or potential interactions.33 On the preclinical 
level, the synergistic effects of antihistamines and corticoids in an 
animal model of AD have been evaluated, finding that the antihista‐
mine olopatadine enhanced the corticoid prednisolone antiinflam‐
matory effect, leading to the conclusion that this drug combination 
could be useful to treat AD, although the mechanism underlying the 
synergism is also unknown.34
7  | CELL SIGNALING PATHWAYS 
CROSSTALK
The ability of a cell to answer internal and external stimuli is a vital 
property. Continuously, each cell of a multicellular organism re‐
ceives a vast number of messages, which are integrated through a 
limited number of signaling pathways to produce complex cellular 
responses. These pathways not only transmit the messages but also 
process and codify them. This reflects the astonishing properties of 
the biological systems to detect stimuli and adapt their biochemical 
machinery upon a wide range of situations to maintain homeostasis. 
This feature compels to conceive cell communication as a complex 
interaction network as of their single components.35
The classical depiction of linear and discrete signaling 
pathways has been replaced by a big amount of multiple inter‐
connected networks, leading to a holistic conception of cell 
communication. However, not all interactions have biological or 
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clinical relevance. In this sense, it is desirable, from a pharmaco‐
logical standpoint, to investigate the crosstalk between signaling 
pathways that could lead to new ways of understanding patholo‐
gies and therapies.36
8  | GPCRS‐ GR CROSSTALK
Modulation	 of	 the	 GR’s	 activity	 has	 been	 extensively	 investi‐
gated since the first report of the receptor appeared in 1967,2 
showing that its activity can be modulated by different signaling 
pathways. In contrast, there are few reports, documenting the 
crosstalk between GR and G‐protein‐coupled receptors (GPCRs) 
signaling at the molecular level. Acting on the β2‐adrenergic re‐
ceptor,	epinephrine	and	nor‐epinephrine	enhances	GR’s	activity	
through Gβγ subunits, PI3K and PKB pathway, but independently 
of its classical effector PKA.37	Somatostatin	suppresses	GR’s	ac‐
tivity directly in the cell nucleus through the binding and nuclear 
translocation of the Gβγ subunits along with the GR.38 Finally, 
it	 has	 been	 reported	 that	melatonin	 suppresses	GR’s	 transcrip‐
tional activity through MT1 receptor‐coupled Gαi subunit,39 
inhibits	 the	 synthesis	 of	 the	 GR’s	 messenger	 RNA,40 prevents 
GC‐induced apoptosis,41	prevents	GR’s	nuclear	translocation	by	
blocking the dissociation from its chaperone Hsp90,42 and af‐
fects its interaction with the coactivator TIF‐2.43 It has been also 
described that the orphan GPCRs, GPR30 and GPR50, modulate 
GR’s	activity,	the	first	one	by	inhibiting	the	expression	of	the	co‐
activator TIF‐2 and the second one, by interacting with coactiva‐
tor TIP‐60.44,45
9  | H1R‐ GR CROSSTALK
Given the pharmacological importance and clinical relevance of anti‐
histamines and corticoids combination therapies, our group focused 
on how H1R signaling pathways modulate GR‐mediated transcrip‐
tional activity. Our results show a complex dual regulation of GR 
activity, consisting of an enhancing effect involving the G‐protein βγ 
subunits and Jun kinase (JNK) and a parallel inhibitory effect medi‐
ated by the canonical Gαq‐PLC‐Rac pathway. An overall activating 
effect is observed when the H1R is activated by its natural agonist, 
histamine, which is the result of a simultaneous triggering of both 
pathways. Conversely, when H1R is bound by inverse agonists, the 
inhibitory Gαq‐PLC‐Rac pathway is repressed, also resulting in an 
enhancement of GR‐mediated transcriptional activity. This paradoxi‐
cal observation that the natural full agonist as well as the H1R inverse 
agonists potentiate GR activity can be explained in terms of the 
mechanism of action proposed (Figure 1). The existence of antihis‐
tamines’	enhancing	effect	was	observed	both	for	GR	transactivation	
and transrepression processes in heterologous expression systems 
through reporter gene assays, and it was replicated in physiopatho‐
logical cell models by measuring the expression of endogenous in‐
flammatory‐related genes.26
10  | PHARMACOLOGIC AL HYPOTHESIS
Based on the previously described findings we hypothesize that the 
enhancement of the GR transcriptional activity by antihistamines 
could allow for a reduction in the GCs doses normally used in the 
clinic. This reduced dose would be ineffective by itself but effec‐
tive in combination with an antihistamine, possibly resulting in new 
therapeutic	strategies	to	treat	different	conditions.	Since	the	dura‐
tion and dosage of treatment with GCs determine the occurrence 
and severity of its adverse effects, a reduction of its dose may result 
in an improvement of its undesired effects without compromising its 
therapeutic efficacy.
11  | POTENTIAL SCENARIOS
The modulation described should only be possible in those cell types 
that coexpresse the H1R and the GR, allowing the interaction of their 
signaling pathways. Among them, endothelial cells, dendritic cells, 
monocytes, neutrophils, B and T lymphocytes, and glial cells are 
examples of GR and H1R coexpression.
46,47 The existence of these 
cell types coexpressing both receptors suggests that this drug as‐
sociation strategy may have many implications in several systems or 
organs such as the immunological system, lungs, skin or the central 
nervous system. Particularly, the inflammatory‐allergic pathologies 
are especially relevant in most of the cell types belonging to the im‐
munological system. The role of dendritic cells in asthma and aller‐
gic rhinitis has been studied for the last fifteen years.48 For its part, 
monocytes, lymphocytes and neutrophils have an important role in 
chronic inflammation of the airways in pathologies such as asthma 
and chronic obstructive pulmonary disease.49‐51 Likewise, endothe‐
lial cells have a crucial role in the development and worsening of 
allergic disorders.52
12  | A STHMA
Besides providing rational support to many of the current thera‐
pies where corticoids and antihistamines are used in combination, 
the description of the GR and H1R signaling pathways crosstalk 
can lead to the development of new therapeutic strategies where 
cotreatment can be justified. Asthma is a high morbidity and mor‐
tality chronic inflammatory disease, and corticoids are currently 
the most effective therapy, but there is a lack of efficacy of an‐
tihistamines in controlling the symptoms.16,53 Therapy with GCs 
is commonly associated with severe adverse effects, especially 
at high doses in long‐term treatments, which often limits their 
use.7 This, together with the existence of asthma patients unable 
to control their symptoms, generates the need for new thera‐
peutic strategies.54 We have studied the effects of the combined 
administration of dexamethasone (DEX) and the antihistamine 
azelastine (AZE) in an allergen‐induced murine model of asthma. 
Our results indicated that the combination of AZE and DEX in a 
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dose ineffective by itself can improve allergic lung inflammation 
as shown by a decrease in eosinophils in bronchoalveolar lavage, 
reduction of peribronchial and perivascular infiltrates and mucin‐
producing cells, diminished serum levels of allergen‐specific IgE 
and IgG1, and a reduction in the expression of inflammation‐re‐
lated genes IL‐4, IL‐5, Muc5AC and Arginase I in the lung.55 The 
finding that AZE potentiated DEX‐induced effects in vivo, leads 
us to suggest that this potentiation might allow for a reduction 
of the GC therapeutic dose needed, supporting the consideration 
of antihistamines as add‐on drugs in GC‐mediated antiasthmatic 
therapies. The potential benefits of the cotreatment consist in a 
reduction of GC‐related adverse effects without losing therapeu‐
tic efficacy.
13  | NEUROINFL AMMATION
Neuroinflammation comprises every inflammatory process that oc‐
curs	 in	the	CNS	and	 involves	distinct	cell	 types	and	mediators	de‐
pending on its onset and progress. Astrocytes and microglia are the 
main	cells	resident	in	the	CNS	responsible	for	the	inflammatory	and	
immunological responses. Their activation induces inflammation 
and release of several mediators including cytokines, chemokines 
or growth factors that originate and sustain the inflammatory 
response.56In general, acute and transient inflammation is a benefi‐
cial	process	that	induces	an	adaptative	response	to	protect	the	CNS	
from an aggression or an injury, while chronic and long‐term inflam‐
mation can lead to the production of neurotoxic mediators. The rise 
in pro‐inflammatory cytokine expression from astrocytes and micro‐
glia inside the brain results in neuroinflammation that ends in neu‐
rodegeneration.57,58 The relationship between neuroinflammation 
and neurodegeneration has been intensely reviewed. In the last few 
years, evidence points to neuroinflammation as an effector in neu‐
ronal dysfunction, cell death and tissue damage.59,60 Moreover, it has 
documented the association between neuroinflammation and neu‐
rodegenerative diseases such as Alzheimer's or Parkinson's diseases 
among others.61,62 The brain has been distinguished as the main tar‐
get of neuroprotective strategies and therefore, the identification 
of glial inflammatory regulators has been recognized for their thera‐
peutic value related to Alzheimer's disease and other neuropatholo‐
gies.63 However, although a lot of evidence supports the relationship 
between neuroinflammation and neurodegeneration, so far there is 
F I G U R E  1   Mechanism of action proposed for the crosstalk between H1R and GR signaling pathways. Activation of the H1R triggers a 
complex dual regulatory mechanism on GR activity, involving both Gαq and Gβγ G‐protein subunits. While the Gαq subunit has an inhibitory 
effect via a PLC‐RAC‐mediated pathway, Gβγ enhances GR activity via JNK. While activation of the H1R by histamine resulted in a composite 
potentiating effect, inactivation of the Gαq‐PLC pathway by H1R inverse agonists resulted in a potentiation of GR activity. The enhancing 
effect of antihistamines occurs both for GR‐mediated transactivation of GRE‐dependent genes and for GR‐mediated transrepression of 
genes regulated by NF‐κB	(p65‐p50).	Solid	lines	indicate	direct	effects;	dashed	lines	indicate	indirect	effects.	Lines	ending	with	arrowheads	
or bars indicate activating or inhibitory effects, respectively. GR: glucocorticoid receptor; H1R: histamine H1 receptor; NF‐κB: nuclear factor 
kappa B; TNF‐α:	tumor	necrosis	factor‐alpha;	LPS:	lipopolysaccharide;	PLC,	phospholipase	C;	JNK:	Jun	kinase;	I‐κB: inhibitor kappa B; GRE: 
glucocorticoid response element; NF‐κB‐RE: NF‐κB response element
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not an effective therapeutic strategy based on this approach. Non‐
steroidal anti‐inflammatory drugs, omega‐3 polyunsaturated fatty 
acids, and immunological antagonists have been clinically evaluated, 
concluding that even though the therapeutic strategy is valid, the 
clinical efficacy is limited.64 Identification of new pharmacological 
targets addressing neuroinflammation will deepen the knowledge of 
these processes and its relation to neurodegenerative diseases, and 
may lead to development of new therapies to treat neuroinflamma‐
tory‐related conditions, many of which lack an adequate or efficient 
therapy. In this sense, there is a potential therapeutic utility for cor‐
ticoids and antihistamines cotreatment in neuroinflammatory con‐
texts. GCs are well‐known to be released as a feedback mechanism 
to quench an inflammatory response, however, more recently they 
have been shown to have proinflammatory effects. Furthermore, the 
effects of chronic exposure to GCs in the brain have been suggested 
to be more complex than its acute antiinflammatory effects in the 
periphery. The roles of histamine and its receptor ligands are also 
complex as well.65 We hypothesize that antihistamines can modulate 
GCs	effects	in	the	CNS	towards	an	antiinflammatory	action,	estab‐
lishing the potentiality of their receptors as targets for the treatment 
of neurodegenerative diseases.
14  | GC‐REL ATED ADVERSE EFFEC TS
Both	GCs’	therapeutic	and	adverse	effects	are	on‐target	and	exerted	
through gene modulation by the GR. Many of the adverse effects 
mainly involve TA processes (glaucoma, hypertension, diabetes) 
while others are the result of TR of genes induced by the GR (hy‐
pothalamic‐pituitary‐adrenal axis suppression, infections suscepti‐
bility).	 Some	of	 them	 involve	 both	mechanisms	 (osteoporosis)	 and	
many others are still not completely elucidated (gastrointestinal 
bleeding and peptic ulcer).6	Since	antihistamines	could	enhance	GC‐
induced GR activity both for TA and TR, it is critical to address the 
potential modulation of GR adverse effects by antihistamines. No 
study is complete if the potential adverse effects are ignored. In con‐
sequence, the adverse effects described before and their underly‐
ing molecular mechanisms must be considered when evaluating the 
safety of antihistamine and corticoid cotreatment.
15  | CONCLUSIONS
The notion supported by molecular evidence obtained in vitro and 
in vivo, that the GR transcriptional activity can be modulated by H1R 
signaling pathways and that this modulation may have therapeutic 
relevance, provides the basis for the pharmacological hypothesis 
proposed herein and invites to go further into the study, aiming to 
address the potential therapeutic application of corticoids and anti‐
histamines cotreatment in different settings. Given that both ligands 
are often used together in several clinical scenarios, it is important 
to investigate the molecular consequences of this drug association, 
especially when multiple pathways are modulated. To understand 
the shared mechanism of action of such widely used drugs is crucial 
to improve their specificity and safety, giving rationale to this com‐
monly associated drug combination.
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